Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Revenue | 28M | 7.7% |
| Gross Profit | 28M | 21.7% |
| Operating expense | 150M | 16.3% |
| Net Income | -112M | 19.1% |
| EBITDA | -122M | 38.6% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 1.16B | 0.5% |
| Total Liabilities | 625M | 6% |
| Total Equity | 531M | 9.5% |
| Shares Outstanding | 98M | 7.3% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -132M | 32% |
| Cash from financing | 142M | 7200% |
EPS
Financial Highlights for Arcus Biosciences in Q1 '25
Arcus Biosciences reported a revenue of 28M, which is a 7.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 28M, marking a 21.7% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Operating Expenses for this period were 150M, showing a 16.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -112M, showing a -19.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -122M, showing a -38.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Arcus Biosciences faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
